High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study.
Elisabeth Schorb, Benjamin Kasenda, Gabriele Ihorst...
https://pubmed.ncbi.nlm.nih.gov/32722778/Actively Recruiting
Led by University Hospital Freiburg · Updated on 2025-02-17
340
Participants Needed
35
Research Sites
104 weeks
Total Duration
Primary diffuse large B-cell lymphoma of the central nervous system PCNSL mainly affects patients aged 60 and above, who often face a poor outlook. This trial compares two treatment options for elderly patients 65 years and older with newly diagnosed PCNSL who are eligible for high-dose methotrexate HD-MTX therapy. The study aims to determine which treatment approach improves survival, response rates, quality of life, and reduces treatment-related side effects in this vulnerable group. One treatment uses the R-MP regimen, which includes rituximab, HD-MTX, and procarbazine given in cycles followed by maintenance procarbazine therapy. The other approach involves a shorter induction treatment with rituximab, HD-MTX, and cytarabine, followed by age-adjusted high-dose chemotherapy and autologous stem cell transplantation HCT-ASCT. Patients receive either three cycles of R-MP plus procarbazine maintenance or two cycles of R-MTXAraC followed by the stem cell transplant procedure with additional chemotherapy drugs. Participants will undergo regular assessments including remission status evaluations after early and later treatment phases, quality of life questionnaires, and long-term monitoring for up to six years. The primary outcome is progression-free survival, with secondary outcomes including overall survival, event-free survival, and quality of life measures. Researchers will also perform geriatric assessments to help define eligibility for the transplant procedure and monitor treatment safety and effectiveness throughout the study period.
CONDITIONS
Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients
E
Elisabeth Schorb, MD
G
Gerald Illerhaus, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital Freiburg
Lead Sponsor
German Federal Ministry of Education and Research
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 9 months (3 cycles of 28-day treatment plus 6 cycles maintenance for R-MP arm; or 2 cycles of 21-day induction plus consolidation for HCT-ASCT arm)
Participants receive one of two chemotherapy treatment regimens: either 3 cycles of conventional immunochemotherapy with R-MP followed by maintenance therapy with procarbazine, or 2 cycles of R-MTX/AraC induction followed by age-adjusted high-dose chemotherapy and autologous stem cell transplantation (HCT-ASCT).
Multiple visits over treatment cycles depending on assigned regimen
Duration - Up to 6 years
Participants are monitored for remission status, quality of life, and long-term survival outcomes for up to 6 years after treatment completion.
Periodic visits as scheduled for assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Elisabeth Schorb, Benjamin Kasenda, Gabriele Ihorst...
https://pubmed.ncbi.nlm.nih.gov/32722778/Elisabeth Schorb, Christopher P Fox, Benjamin Kasenda...
https://pubmed.ncbi.nlm.nih.gov/31997308/Gaelle Olivier, Aline Clavert, Laurence Lacotte-Thierry...
https://pubmed.ncbi.nlm.nih.gov/25052698/Caroline Houillier, Carole Soussain, Hervé Ghesquières...
https://pubmed.ncbi.nlm.nih.gov/31907289/Andrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski...
https://pubmed.ncbi.nlm.nih.gov/29054815/Elisabeth Schorb, Lisa Kristina Isbell, Andrea Kerkhoff...
https://pubmed.ncbi.nlm.nih.gov/38301670/Joe S Mendez, Quinn T Ostrom, Haley Gittleman...
https://pubmed.ncbi.nlm.nih.gov/29036697/Andrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski...
https://pubmed.ncbi.nlm.nih.gov/27132696/Jonathan Farhi, Kamel Laribi, Corentin Orvain...
https://pubmed.ncbi.nlm.nih.gov/30091022/Antonio Omuro, Olivier Chinot, Luc Taillandier...
https://pubmed.ncbi.nlm.nih.gov/26688235/University Hospital Freiburg
Lead Sponsor
German Federal Ministry of Education and Research
Collaborating Sponsor